Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyPhenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter PyloriImplementing genotype-guided antithrombotic therapy.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyEffects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismEffect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary interventionPharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosusRelationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian populationGenetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populationsReliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisMolecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineGenetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsGenetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.
P2860
Q26823542-38302124-B1C6-43AD-B77B-EBA55D1C8CB7Q28362533-8BFB7363-C31D-45B6-881B-6102412983E3Q33290485-2837BFC1-0ACC-474F-9AD7-EB10C02AB781Q33787853-68D1C996-8B28-45B0-BE9E-EDEA22AAA254Q33990428-6388D0F3-16BD-4C1A-9987-B3D611357E0AQ34019082-E1CE4981-8F41-4FFC-9F18-7CC597611FA7Q34213621-AE50E824-E561-4950-A787-669814B22232Q35122933-666D0022-61CC-4F05-89FA-611694EB1ACCQ35364006-86C2381B-58DE-4914-9585-174B7F58D22DQ35548495-1191B5E5-B5DF-46FD-9162-8E6CADF664EDQ35802629-E59F42C7-07EB-431D-A09C-6101C29B310EQ35825569-377A1D1A-0CC6-410A-ACC0-EB6D33C4C1C5Q36053279-DC4A0E73-05CA-47BF-932A-FB9F3C0313C7Q36062323-852CD6A6-5E7F-4ED8-9D7B-85FD8EAB2680Q36307008-6E8260C7-5B71-4EFE-8ED2-4EBF0B6ACC1DQ36580034-8298A3B2-26FC-46EB-8E41-F074FF62593DQ36802054-DC6C7AAB-9148-4922-9345-3199C0F66EEFQ37140633-422700FE-88E2-476E-B146-2924DB9B90C3Q41595607-4DFDCCA3-6009-4B11-BF0E-E6193622B59AQ47231767-B4CCE097-BC9C-4366-A336-926453271627Q47554139-79D7EF10-0268-4C3C-BD78-E504914BB972
P2860
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
description
1997 nî lūn-bûn
@nan
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@ast
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@en
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@nl
type
label
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@ast
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@en
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@nl
prefLabel
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@ast
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@en
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@nl
P2093
P1476
Differences in the incidence o ...... new rare CYP2C19 mutant allele
@en
P2093
J A Goldstein
J Blaisdell
P304
P407
P577
1997-04-01T00:00:00Z